Researchers at Black Dog Institute are leading the TRIP-D trial, exploring psilocybin-assisted therapy as a new treatment for treatment-resistant depression (TRD). The trial takes a novel approach, allowing participants to continue their existing antidepressants while receiving psilocybin at escalating doses. Building on the Institute’s pioneering work with ketamine treatment, which has already transformed care for people with TRD, this research represents the next step toward expanding effective options for the 30% of people with depression who don’t respond to standard medications. 👉 Read our full article here: https://bit.ly/4hHmvpL #mentalhealth #healthprofessionals #research #treatment
Black Dog Institute leads psilocybin-assisted therapy trial for TRD
This title was summarized by AI from the post below.
